IBI-363

N/A

Report date: 2026/05/18 10:24:54
First In Class

Base Information

Drug NameIBI-363
Drug Alias NameIBI-363
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-PD-1 +[4] 
TargetsProgrammed cell death protein 1Interleukin-2
Therapy Area/IndicationsMucosal MelanomaGastroesophageal Junction NeoplasmsSolid tumours +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesInnovent Biologics IncShanghai Pulmonary Hospital +[10] 
Inactive CompaniesN/A
Active IndicationsMucosal MelanomaGastroesophageal Junction NeoplasmsSolid tumours +[11] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A